35% of acute cases and 73% of non-hospitalized convalescent COVID-19 cases fulfilled the ADIM 3 group criteria of successful SARS-CoV-2-specific neutralizing antibody, CD4+ T cell, and CD8+ T cell responses. This evidence concerns the gene CD4 and COVID-19.